Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Core Viewpoint - Pharming Group N.V. has received a positive opinion from the CHMP of the EMA recommending marketing authorization for Joenja® (leniolisib) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 years and older, marking a significant advancement in APDS care in Europe [1][3][6]. Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare and life-threatening diseases, headquartered in Leiden, the Netherlands [10]. Product Information - Joenja® (leniolisib) is an oral small molecule PI3Kδ inhibitor, currently approved in the U.S., U.K., Australia, and Israel for patients aged 12 years and older with APDS, and in Japan for patients aged 4 years and older [8][4]. - The positive CHMP opinion is based on a Phase II/III clinical trial involving 31 patients, demonstrating a statistically significant impact on immune dysregulation and immunodeficiency [3][6]. Market Potential - If approved by the European Commission, Joenja would be the first treatment for APDS in the European Union, with centralized marketing authorization valid across all 27 EU Member States, Norway, Iceland, and Liechtenstein [2][6]. Clinical Insights - The clinical program for leniolisib has shown meaningful improvements in immune dysregulation and deficiency, suggesting it could significantly change the clinical outlook for patients with APDS [4][3]. - APDS affects approximately 1 to 2 individuals per million worldwide, and patients often experience a median diagnostic delay of 7 years [7][5].